Sort   by:  
 Page size 
UnknownChronic lung diseases are associated with gene expression programs favoring SARS-CoV-2 entry and severity.
Not available
S-EPMC8280215 | biostudies-literature
UnknownChronic lung diseases are associated with gene expression programs favoring SARS-CoV-2 entry and severity.
Not available
S-EPMC7587778 | biostudies-literature
UnknownLong-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.
Not available
S-EPMC9857594 | biostudies-literature
UnknownEffect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
Not available
S-EPMC8941448 | biostudies-literature
UnknownEffect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.
Not available
S-EPMC10326520 | biostudies-literature
UnknownAn integrated cell atlas of the lung in health and disease.
Not available
S-EPMC10287567 | biostudies-literature
UnknownEffect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
Not available
S-EPMC8491132 | biostudies-literature
UnknownEffect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.
Not available
S-EPMC7489418 | biostudies-literature
UnknownLongitudinal Multi-omics Analyses Identify Responses of Megakaryocytes, Erythroid Cells, and Plasmablasts as Hallmarks of Severe COVID-19.
Not available
S-EPMC7689306 | biostudies-literature
UnknownLopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.
Not available
S-EPMC8274471 | biostudies-literature
Sort   by:  
 Page size